Related Experiment Video

Updated: Jan 5, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.1K

Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy

Debasis Das1, Mayank Pandya1

  • 1Department of Chemistry, School of Science, RK University, Rajkot-360020, Gujarat, India.

Mini Reviews in Medicinal Chemistry
|September 14, 2017
PubMed

Insights

Direct-acting antiviral agents (DAAs) offer effective, interferon-free treatment for chronic Hepatitis C virus (HCV) infection. This review covers clinical trial results of new DAAs and approved combinations, including their advancements and side effects.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic Hepatitis C virus (HCV) infection affects 170-200 million globally, posing risks for liver cirrhosis and cancer.
  • Complete HCV eradication is a primary goal of antiviral research.
  • First-generation protease inhibitors (boceprevir, telaprevir) were approved in 2011.

Purpose of the Study:

  • To review clinical trial results of direct-acting antiviral agents (DAAs) for Hepatitis C.
  • To discuss approved DAA combinations and their efficacy.
  • To cover the latest advancements and side effects of DAA therapy.

Main Methods:

  • Review of clinical trial data for various DAAs.
  • Analysis of approved combination therapies.
  • Discussion of drug classes: NS3/4A protease inhibitors, NS5A inhibitors, and NS5B inhibitors.

Main Results:

  • New DAAs demonstrate increased efficacy, safety, and tolerability.
  • Interferon-free oral therapies are now standard for chronic HCV and cirrhosis.
  • Several DAA medications (Sovaldi®, Harvoni®, Viekira Pak®, Epclusa®, Zepatier®) have received FDA approval.

Conclusions:

  • DAAs represent a significant advancement in Hepatitis C treatment.
  • Interferon-free regimens have transformed HCV management.
  • Ongoing research focuses on optimizing DAA therapy and managing potential side effects.

Keywords:
DAADrugHCVNS3NS3/4ANS4ANS5ANS5B.hepatitis C virusinhibitor

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.7K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.3K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
228
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
445
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K